GlassScriptPhysician profile
Ali A Chaudhry
NPI 1295112191
$2,399.70
in general payments reported to CMS, 2019-2025
18 companies · $1,565 in 2025
The $1,565 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180 · 2022: $141 · 2023: $46.13 · 2024: $468 · 2025: $1,565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,979 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,978.56 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $407.24 | 2024-2025 | Acthar |
| Glaxosmithkline, LLC. | $371.90 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $224.78 | 2025 | Fasenra, Airsupra, Breztri |
| Viatris Specialty LLC | $204.40 | 2025 | Yupelri |
| Verona Pharma, INC. | $182.61 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $148.82 | 2019-2025 | Zerbaxa, Dificid |
| Endologix LLC | $141.38 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $136.60 | 2023-2025 | Glassia |
| Insmed, INC. | $121.68 | 2025 | Arikayce |
| Genentech USA, INC. | $86.09 | 2019 | |
| Melinta Therapeutics, LLC | $84.64 | 2024 | Rezzayo, Orbactiv, Kimyrsa |
| Regeneron Healthcare Solutions, INC. | $79.84 | 2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.19 | 2019-2025 | Ofev, Jascayd |
| Lilly USA, LLC | $36.54 | 2025 | Zepbound |
| Inspire Medical Systems, INC. | $34.64 | 2025 | Inspire |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $32.85 | 2024 | |
| United Therapeutics Corporation | $19.33 | 2025 | Tyvaso |
| Genzyme Corporation | $15.17 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Chaudhry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.